Special Issue

Gestational Diabetes: Challenges and Cutting-Edge Research

Message from the Guest Editors

Gestational Diabetes represents a serious health issue with a global prevalence of between 1% and 14%. Several factors play crucial role such as lactogenic hormone secreted from placenta, which desensitizes insulin and increases glucose levels during the final trimester; cortisone; estrogen and other hormones; maternal age; and genetic predisposition. When gestational diabetes is not recognized or not properly managed, it leads to an increased risk of certain conditions affecting both mother and newborn, such as pre-eclampsia, polyhydramnios, and fetal macrosomia.

This Special Issue will examine recent challenges in the diagnosis and management of gestational diabetes. In particular, we would appreciate original articles and literature reviews investigating novel potential pathophysiological mechanisms underlying gestational diabetes or advanced therapeutic approaches. Furthermore, studies exploring new molecular pathways with potential therapeutic applications or studies using Al for monitoring and treating pregnant women are welcome.

Guest Editors

Dr. Athanasios N. Tsartsalis

Department of Endocrinology Diabetes and Metabolism, Naval Hospital of Athens, Deinokratous 70, 11521 Athens, Greece

Dr. George I. Lambrou

Choremeio Research Laboratory, First Department of Pediatrics, National and Kapodistrian University of Athens, Thivon & Levadeias 8, Goudi, 11527 Athens, Greece

Deadline for manuscript submissions

15 October 2025



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/230278

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

